Skip to main content

Table 1 Patient characteristics for SARS-CoV-2-infected patients randomized to early (≤ 7 days) or late (≥ 10 days) tracheotomy (intention-to-treat population) in the TTCOV19 study

From: TTCOV19: timing of tracheotomy in SARS-CoV-2-infected patients: a multicentre, single-blinded, randomized, controlled trial

 

Total

Early tracheotomy

Late tracheotomy

(n = 150)

(n = 72)

(n = 78)

Age, years

64.6 (11.4)

64.3 (12.4)

64.9 (10.5)

65.5 (58;74)

65 (57.5;74.5)

65.5 (59;73)

n = 150

n = 72

n = 78

Male sex

118 (78.7%)

57 (79.2%)

61 (78.2%)

Female sex

32 (21.3%)

15 (20.8%)

17 (21.8%)

Body-mass index, kg/m2

33.4 (19.5)

31.3 (6.3)

35.2 (26.2)

30.6 (27.2;34.5)

30.7 (27.3;33.8)

30.8 (27.1;35.5)

n = 146

n = 69

n = 77

SAPS3*

50.8 (8.0)

51.2 (8.8)

50.5 (7.2)

50 (45;55)

50 (45;57)

50 (46;55)

n = 147

n = 70

n = 77

Covid-19 medication

No

134 (90.5%)

66 (91.7%)

68 (89.5%)

Remdesivir

11 (7.4%)

4 (5.6%)

7 (9.2%)

Tocilizumab

3 (2.0%)

2 (2.8%)

1 (1.3%)

Coexisting illness

Heart disease

34 (22.7%)

16 (22.2%)

18 (23.1%)

Hypertension

85 (56.7%)

36 (50.0%)

49 (62.8%)

Asthma

26 (17.6%)

13 (18.3%)

13 (16.9%)

Chronic obstructive pulmonary disease

8 (5.3%)

4 (5.6%)

4 (5.1%)

Obstructive sleep apnoea syndrome

12 (8.0%)

5 (6.9%)

7 (9.0%)

Diabetes

46 (30.7%)

19 (26.4%)

27 (34.6%)

  1. Data are expressed as the mean (SD), median (IQR) or n (%)
  2. *SAPS3 Simplified Acute Physiology Score 3
  3. Heart failure or coronary artery disease